|GSK Lung Drug Fails to Meet Primary Goal in Clinical Trial|
|By Staff and Wire Reports|
|Wednesday, 16 September 2015 12:39|
GlaxoSmithKline’s Breo Ellipta failed to meet its primary goal in a pivotal clinical trial of curbing death risk in patients suffering from chronic pulmonary obstructive disease.
The British pharmaceutical giant said last week that the risk of death was 12.2 percent lower among patients receiving the treatment versus placebo, but the results were not statistically significant to prove its ability in extending life.
The study began in 2011 and tracked 16,485 people from 43 countries who had chronic obstructive pulmonary disease, and either a comorbidity or risk of cardiovascular disease. Cardiovascular disease has been shown to double mortality in COPD patients.